Jefferies Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Jefferies Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,200	Closed	-$271K	–	1791
2021 Q4	$271K	Buy	+3,200	New	+$263K	﹤0.01%	1314
2020 Q3	–	Sell	-5,000	Closed	-$566	–	1470
2020 Q2	$566	Hold	5,000	–	–	0.01%	883
2020 Q1	$334K	Sell	5,000 -16,800	-77%	-$1.4M	﹤0.01%	1491
2019 Q4	$1.99M	Sell	21,800 -15,700	-42%	-$1.52M	0.02%	1063
2019 Q3	$3.23M	Sell	37,500 -25,500	-40%	-$2.39M	0.03%	761
2019 Q2	$6.6M	Buy	63,000 +5,700	+10%	+$611K	0.05%	360
2019 Q1	$7.18M	Buy	57,300 +13,300	+30%	+$1.65M	0.06%	302
2018 Q4	$4.96M	Buy	44,000 +30,000	+214%	+$4.64M	0.04%	419
2018 Q3	$3M	Buy	+14,000	New	+$3.51M	0.02%	787
2013 Q4	–	Sell	-1,969	Closed	-$435K	–	2102
2013 Q3	$435K	Buy	+1,969	New	+$419K	﹤0.01%	1253

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jefferies Group's MDGL Position: Q3 2021 in Review

Jefferies Group sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2021, closing a stake of 5,023 shares — an estimated $489K sold.

Jefferies Group first reported a position in MDGL in Q3 2013 and held it in 19 quarters. The position peaked at $6.29M in Q1 2015. 133 funds tracked by Wall St. Rank hold MDGL as of Q3 2021.

Jefferies Group reported no remaining Madrigal Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Jefferies Group sold 5,023 Madrigal Pharmaceuticals shares in Q3 2021, an estimated $489K.
Jefferies Group first reported a position in Madrigal Pharmaceuticals in Q3 2013 and held it in 19 quarters.
Jefferies Group's Madrigal Pharmaceuticals position peaked at $6.29M in Q1 2015.
133 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.